Essetifin buying at Fennec Pharmaceuticals (FRX)

Essetifin buying at Fennec Pharmaceuticals (T:FRX)

Essetifin S.p.a., a 10% Holder, acquired 300,000 Common Shares on a direct ownership basis at a price of US$4.00 through a private transaction on June 8th, 2017. This represents a $1,620,360 investment into the company's shares and an account share holdings change of 11.4%.

Fennec Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.